Apogee Therapeutics, Inc. APGE 深 沪
已收盘 07-02 16:00:00 美东时间
132.91
+0.140
+0.11%
华盛通- 最 高133.85
- 今 开133.60
- 成交量 299.88万股
- 最 低 132.73
- 昨 收 132.77
- 总市值 100.20亿
- 52周最高 133.85
- 市盈率 静 --
- 换手率 3.98%
- 52周最低 34.34
- 委 比 34.47%
- 总股本 7538.94万
- 历史最高 133.85
- 量 比 0.66
- 振 幅 0.84%
- 历史最低 14.19
- 每 手 1
- 风险率 21.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Are APGE, INVE, CBAN, FSRL Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
07-03 03:38
美股月度涨跌榜 | 半导体设备巨头疯涨！应用材料月内暴涨60%、科磊暴涨57%；迈威尔科技获黄仁勋“喊单”
半导体设备巨头疯涨！应用材料月涨60%、科磊暴涨57%；迈威尔科技获黄仁勋“喊单”月内暴涨45%，光通信股表现炸裂！康宁月涨超40%>>
07-01 17:32
美股周涨跌榜 | 航天巨头DPC上市首周飙涨46%！黑莓业绩大超预期，股价周涨36%
航天巨头DPC上市首周飙涨46%！黑莓业绩大超预期，上调全年营收展望，股价周涨36%；艾伯维斥资109亿美元收购APGE>>
06-27 12:00
美股大行评级 | 瑞银上调超微公司目标价从455美元升至670美元，上调ARM目标价从260美元升至470美元；美银证券上调台积电目标价从490美元升至590美元
今日重点评级关注：Jones Trading：维持Definium Therapeutics"买入"评级，目标价从61美元升至74美元；韦德布什：维持Cerebras Systems"跑赢大市"评级，目标价从270美元升至280美元
06-25 11:32
美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst
On Monday, biopharmaceutical giant AbbVie Inc. (NYSE:ABBV) agreed to acquire Apogee Therapeutics Inc. (NASDAQ:APGE) in a cash deal valued at approximately $10.9 billion. The deal comes as the largest after AbbVie acquired Botox maker Allergan for a massive $63 billion. In 2023, AbbVie acquired cance...
06-24 01:11
Wedbush Downgrades Apogee Therapeutics to Neutral, Maintains Price Target to $135
Wedbush analyst David Nierengarten downgrades Apogee Therapeutics (NASDAQ:APGE) from Outperform to Neutral and maintains the price target from $135 to $135.
06-23 20:16
美股牛股 | 一纸协议引GETY飙涨90%！与OpenAI就图库授权达成合作；APGE涨超46%
一纸协议引GETY飙涨90%！与OpenAI就图库授权达成合作；APGE涨超46%，获艾伯维斥资109亿美元收购；DFTX涨近50%>>
06-23 19:12
Are ACA, CZR, APGE Obtaining Fair Deals for their Shareholders?
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
06-23 04:20
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
Read Also: AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients Biopharmaceutical giant AbbVie Inc. (NYSE:ABBV) announced Monday that it has agreed to acquire Apogee Therapeutics Inc. (NASDAQ:APGE) in a cash deal valued at approximately $10.9 billion. The deal strengthens it...
06-22 21:15
